Aptamer Group PLC Half Year Trading Update (4078L)
January 03 2023 - 1:00AM
UK Regulatory
TIDMAPTA
RNS Number : 4078L
Aptamer Group PLC
03 January 2023
3 January 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS
PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 ("MAR").
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Half Year Trading Update
Aptamer Group plc (AIM: APTA), the developer of novel Optimer(R)
binders to enable innovation in the life sciences industry, today
announces a trading update for the six months ended 31 December
2022 (H1 23).
As reported previously, 2022 has seen significant progress for
Aptamer with the investment in new facilities to create more
capacity and an expanded team, especially in sales and marketing.
The benefit of this investment is apparent in a very healthy
pipeline and level of enquiries for 2023, despite the challenging
macro-economic conditions.
Revenues are generally expected to be second half weighted owing
to typical seasonality of customer budgets, but this has been
exacerbated in 2022 due to a number of factors including customer
delays and general economic conditions. As a result, revenues in
the first half are expected to be in the region of GBP1.0m.
However, the Group has good visibility on its commercial pipeline
going into the second half, including a further GBP1.0m of current
signed orders, as well as contracts in negotiation and strong
expressions of interest across all three business units.
The Group remains focused on delivering market expectations for
the full year but acknowledges that the headwinds experienced in
the first half may continue into 2023 and that revenue for the full
year may fall below market expectations, but materially ahead of
the level achieved last financial year.
Further updates will be provided as the Company progresses
through the second half.
Dr Arron Tolley, Chief Executive Officer, commented: "Our highly
active deal pipeline demonstrates the clear market opportunity and
demand for Optimers across the life sciences industry. In the
current challenging economic environment, by offering our customers
significant cost savings as they develop therapies and diagnostic
products and conduct research activities, we expect to generate
increasing revenue through paid R&D activities, IP licensing
deals and success-based milestone payments. We look forward to
providing further updates to the market as these opportunities
convert."
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Cara Murphy +44 (0) 20 3100 2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer(R) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global antibody market is
currently worth over $145.0 billion. Optimer binders are engineered
to address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global
pharma companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions
that support discovery and development across the Life
Sciences.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTUUUAROAUARUR
(END) Dow Jones Newswires
January 03, 2023 02:00 ET (07:00 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024